INTERNATIONAL PATENT: HANMI PHARM. CO., LTD., 한미약품 주식회사 FILES APPLICATION FOR "TRIPLE AGONIST HAVING ACTIVITY FOR GLP-1, GIP AND GLUCAGON RECEPTORS AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPRISING SAME"

GENEVA, Dec. 23 -- HANMI PHARM. CO., LTD. (214, Muha-ro, Paltan-myeon,Hwaseong-si,Gyeonggi-do 18536), 한미약품 주식회사 (경기도화성시팔탄면 무하로 214) filed a patent application (PCT/KR2025/008183) for "TRIPLE AGONIST HAVING ACTIVITY FOR GLP-1, GIP, AND GLUCAGON RECEPTORS AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPRISING SAME" on Jun 13, 2025. With publication no. WO/2025/259063, the details related to the patent application was published on Dec 18, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Inte...